Company Overview and News
(Oct 18): ABB Ltd is working with advisers to prepare the potential separation of its power grid unit, people familiar with the matter said, which would be a strong indication the Swiss engineering company may divest the business worth more than US$10 billion.
DGLD CS GS UGLD GLSSP ABLZF JBK DSLV VIIX GSC CSSLF VIIZ TFG GSJ CSGKF ABB ZIV USLV TVIX GJS XIV
We issued a research report on ABB Ltd. (ABB - Free Report) on Oct 1. This power and automation technology provider currently has approximately $50 billion market capitalization. Few growth drivers and certain headwinds, which might influence ABB, have been discussed below. Factors Favoring ABB Financial Performance & Earnings Outlook: ABB pulled off an average positive earnings surprise of 12.03% for the last four quarters.
FLOW ABB ESE ABLZF IPWR
Spun off from Pentair, nVent is now free to reinvest some of its above-average margins into projects that can drive better revenue growth.
Recently,Cimpress N.V. (CMPR - Free Report) inked a definite agreement to acquire BuildASign — a premium online provider of signage, canvas wall décor and other types of large format products. This $280-million buyout is in sync with the company’s merger & acquisition strategy, and will likely strengthen its Print, Upload and Vistaprint businesses, moving ahead.
ABB ADES ATKR ABLZF
Cintas Corporation (CTAS - Free Report) has announced that it will conduct the groundbreaking ceremony for marking the construction site of its new manufacturing facility in Delta Township. The ceremony will be held on Sep 24 at 1:00 p.m., at the southwest corner of Mt. Hope Highway and S. Canal Road.
CTAS ABB ADES ATKR ABLZF TITN
The Timken Company (TKR - Free Report) , successfully acquired premium engineered linear motion product manufacturer — Rollon Group, on Sep 18, Financial terms of the transaction have not been disclosed. Share price of the company spiked nearly 2% to $49.50 per share, after news of the acquisition surfaced.
ABB ABLZF TKR LB TRS
WallStars are distinguished by positive broker target-price upsides. 'Safer' dividend industrials WallStar 1yr. target=gains for DAL, CAT, MAN, TTEC, CMRE, GMLP, DLX, CPA, GMLP. CPLP, & ATTO ranged 19.88%-68.45%.
CPLP HMLP CAT MAN SFL WM BGSF ABB CMRE GMLP CAJ ABLZF DLX DAL
2018 has been a strange time for investors. While the U.S. stock market sits close to all-time highs, many of the emerging and other developed markets nations have seen their shares take a beating. Wall Street analysts have made numerous calls signaling that there now may be more upside and opportunities in some larger international companies.
BLT BHPBF BP BP.A BP.B ABB BP BHP CCE ABLZF BBL TRI BHP MS BPAQF BHPLF
2018-08-14 zacks - 1
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 12 major stocks, including UnitedHealth (UNH), PepsiCo (PEP) and Amgen (AMGN). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
FOX GD AMGN CQP LNG CVS CLH ABB 7018 PEP AMT CME ABLZF TXT UNH FOXA
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
SBGSY DSLV GEC GE CATR VIIX DGLD CAT CSSLF VIIZ CS SBGSF BHI CSGKF ABB UGLD ABLZF GNE ZIV USLV TVIX XIV
2018-08-08 investorplace - 2
Investing for income usually results in quieter, and lower-risk, investment strategies. The best dividend stocks tend to be more mature and lower-growth, which is why they distribute cash to shareholders rather than reinvesting it in their businesses. The goal of most income investors is to protect principal by buying quality companies who will grow dividends over time, rather than chasing ‘hot’ stocks with higher risk.
IBM HON GE F GEC ETH SCS ABB MAT AMZN FTRPR HON MLHR ABLZF TSLA GNE SPG EMR KNL SSI GMAN MAC FTR
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to ABB / ABB Ltd. on message board site Silicon Investor.
as of ET